You are here



An International Journal
Other Titles in:
Immunology | Lupus Erythematosus

eISSN: 14770962 | ISSN: 09612033 | Current volume: 33 | Current issue: 6 Frequency: 14 Times/YearTimes/Year

The only fully peer reviewed international journal devoted exclusively to lupus (and related disease) research. Lupus includes the most promising new clinical and laboratory-based studies from leading specialists in all lupus-related disciplines.

If you wish your article to be freely available online immediately upon publication (as some funding bodies now require), you can opt for it to be included in SAGE Choice upon payment of a publication fee. Manuscript submission and refereeing procedure is unchanged, but on acceptance of your article you will be asked to let SAGE know directly if you are choosing SAGE Choice.

If funding has been provided for your research, convention dictates that you acknowledge the source and grant information in the Acknowledgements section of your article. Please note that in some cases, grant funders require authors to attribute the funding source, describe the role of the study funding body and include the relevant grant reference numbers.

For further information please visit http:/

This journal is a member of the Committee on Publication Ethics (COPE).

The only fully peer-reviewed international journal devoted exclusively to lupus (and related disease) research.

Lupus includes the most promising new clinical and laboratory-based studies from leading specialists in all lupus-related disciplines.

Invaluable reading, with extended coverage, lupus-related disciplines include:

  • Rheumatology
  • Dermatology
  • Immunology
  • Obstetrics
  • Psychiatry
  • Cardiovascular Research

Leading international specialists present their findings on Lupus, in one outstanding reference.

Graham RV Hughes Head of London Lupus Centre
Associate Editors
Munther Khamashta Head of Lupus Clinic, Rheumatology Department, Dubai Hospital, UAE
S Sciascia University of Torino, Italy
Managing Editors
Maria Laura Bertolaccini St Thomas' Hospital, UK
Editorial Board
GS Alarcon The University of Alabama at Birmingham, USA
P Alba Hospital Cordoba, Rheumatology
M-C Amigo National Institute of Cardiology, Mexico
S Appenzeller State University of Campinas, Internal medicine
T Atsumi Hokkaido University Graduate School of Medicine, Japan
S Bombardieri University de Pisa, Rheumatology
DT Boumpas University of Crete, Greece
JP Buyon New York University, USA
R Cervera Hospital Clinic 1 Provincial, Internal Medicine
DTM Chan University of Hong Kong, Medicine
R Cimaz University of Milan, Italy
David D’Cruz St Thomas' Hospital, UK
Fereydoun Davatchi Tehran University of Medical Science, Iran
A Doria University of Padova, Italy
T Dorner Department of Medicine, Charita Berlin
C Edwards Southampton General Hospital, UK
K Elkon Cornell Medical College, USA
D Erkan Hospital for Special Surgery, Rheumatology
Pao-Hsii Feng Tan Tock Seng Hospital, Singapore
C Flower Queen Elizabeth Hospital, Medicine
MJ Fritzler University of Calgary, Canada
Dr Antonio Gil La Paz Hospital, Madrid
J Gomez-Puerta Universidad de Antioquia Grupo de Inmunologia Celular et Immunogenetica
BH Hahn University of California, Los Angeles, USA
JG Hanly Dalhousie University, Canada
EN Harris University of the West Indies, Jamaica
E. Hess University of Cincinnati, USA
FA Houssiau Catholic University of Louvain, Belgium
O. Hubscher CEMIC, Argentina
BJ Hunt St Thomas' Hospital, UK
Meenakshi Jolly,MD, MS Rush University, USA
JR Kalden F.A.-University Erlangen-Nurnberg, Germany
A Kaul St George's Hospital and Medical School, UK
T Koike Hokkaido University, Japan
S. Krilis St George Hospital, Australia
A Kuhn University Medical Center Mainz, Mainz, Germany
V Kyttaris Beth Israel Medical Center, USA
Robert G Lahita MD, PhD, FACP, MACR, FRCP Chairman of Medicine
CS Lau China
R Levy UERJ Rhematology
MH Liang Brigham and Women's Hospital, USA
MD Lockshin Cornell Medical College, USA
AN Malaviya Arthritis & Rheumatism Clinic, Rheumatology
PL Meroni University of Milan, Italy
T Millard Gloucestershire Royal hospital
CC Mok Tuen Mun and Pok Oi Hospital, New Territories, Hong Kong
Javier Molina Health Sciences Institute - CES, Colombia
G Moroni Fondazione IRCCS Cà Granda Ospedale Maggiore Milano, Italy
V Moulton Beth Israel Deacones Medical Center, Medicine/Rheumatology
H. Moutsopoulos University of Athens, Greece
A.L. Parke University of Connecticut Health Cent, USA
M Petri Johns Hopkins University, USA
Jean-Charles Piette Salpetriere Hospital, France
A Rahman University College London, UK
R. Rubin University of New Mexico, USA
G Ruiz-Irastorza Hospital de Cruces, Spain
JE Salmon Hospital for Special Surgery, USA
PH Schur Brigham and Women's Hospital, USA
GD Sebastiani Azienda Ospedaliera San Camillo - Forlanini, Italy
Y Shoenfeld Sheba Medical Center, Tel-Hashomer, Israel
R. Smeenk Sanquin Diagnostic Services, Netherlands
JS Smolen Medical University of Vienna, Austria
Richard Sontheimer University of Iowa, USA
L Stojanovich Bezanijska Kosa Medical Center, Internal Medicine/Rheumatology
V Strand Stanford University, USA
T. Swaak Zuiderziekenhuis, Rotterdam, Netherlands
M Tektonidou National University of Athens, Greece
GC Tsokos Beth Israel Deaconess Medical Center, USA
L Tucker United States
MB Urowitz University of Toronto, Canada
S Vasoo Division of Rheumatology, Department of Medicine, National University Hospital, Singapore
D Wallace Cedars-Sinai Medical Center, USA
P Youinou University of Brest, France
  • Academic Search Premier
  • BIOSIS Previews Database
  • BIOSIS database
  • Biological Abstracts Family of Products
  • Clarivate Analytics: BIOSIS Previews
  • Clarivate Analytics: Biological Abstracts
  • Current Citations
  • Current Contents / Clinical Medicine
  • EMBASE/Excerpta Medica
  • Elsevier BIOBASE/Current Awareness in Biological Sciences
  • ISI Discovery Agent
  • Index Medicus
  • Index Medicus (Ceased 2004)
  • Science Citation Index
  • Science Citation Index Expanded
  • Scopus
  • Manuscript Submission Guidelines: Lupus

    This Journal is a member of the Committee on Publication Ethics.

    This Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals formulated by the International Committee of Medical Journal Editors (ICMJE).

    Please read the guidelines below then visit the Journal’s submission site to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned.

    Only manuscripts of sufficient quality that meet the aims and scope of Lupus will be reviewed.

    There are no fees payable to submit or publish in this Journal. Open Access options are available - see section 3.3 below.

    As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you.

    1. What do we publish?
      1.1 Aims & Scope
      1.2 Article types
      1.3 Writing your paper
    2. Editorial policies
      2.1 Peer review policy
      2.2 Authorship
      2.3 Acknowledgements
      2.4 Funding
      2.5 Declaration of conflicting interests
      2.6 Research ethics and patient consent
      2.7 Clinical trials
      2.8 Reporting guidelines
      2.9 Data
    3. Publishing policies
      3.1 Publication ethics
      3.2 Contributor's publishing agreement
      3.3 Open access and author archiving
    4. Preparing your manuscript
      4.1 Formatting
      4.2 Artwork, figures and other graphics
      4.3 Supplementary material
      4.4 Reference style
      4.5 English language editing services
    5. Submitting your manuscript
      5.1 ORCID
      5.2 Information required for completing your submission
      5.3 Permissions
    6. On acceptance and publication
      6.1 Sage Production
      6.2 Online First publication
      6.3 Access to your published article
      6.4 Promoting your article
    7. Further information

    1. What do we publish?

    1.1 Aims & Scope

    Before submitting your manuscript to Lupus, please ensure you have read the Aims & Scope.

    1.2 Article Types

    Lupus is published fourteen times a year. The Editor will consider for publication all suitable papers dealing directly or indirectly with lupus or related diseases. The journal publishes both clinical and non-clinical research papers. Original research articles should be limited to no more than 4,000 words, 50 references and 6 tables and/or figures. They will be peer reviewed by two referees. In addition to original papers, the journal also publishes editorials, reports, and letters.

    Editorials are solicited by the Editor but suggestions for such material will be very welcome.

    The purpose of a grand rounds submission is to educate the reader about one or more facets related to the disease lupus or of an autoimmune disease which is related to lupus. A clinicopathological conference can be submitted but this must have postmortem data and is usually a death conference or mortality conference.
    Avoid extraneous material which has little bearing on the case at hand. The readers wish to learn about every facet of the case presented and not about other unrelated material.

    The submitted case should contain:
    Introduction - This should be no more than one or two short paragraphs and summarise what is about to be presented and the reasons why the case was chosen.
    Case Presentation - This part contains a succinct narrative of the case itself. Figures, photographs and tables with data are welcome. Also encouraged are data on biopsies with illustrative materials if possible.
    Discussion - The discussion should be a focused presentation of theory and/or pathogenetic data regarding the case.
    Final Diagnosis - This should be only one sentence which gives the final diagnosis.

    These should be short investigative papers and reports organised in the same way as full-length manuscripts but which contain 2000 words or less, with no more than 3 figures or tables and up to 15 references.

    The Editor will consider for publication case reports that illustrate points not previously reported in the literature. They should not exceed two printed pages in length. The number of references should not exceed ten.
    The number of case reports published in Lupus will be strictly limited.

    Letters to the Editor are encouraged. They may deal with material in published papers or they may raise new issues. Short clinical or laboratory observations may also be presented as Letters.
    Letters must contain no more than 500 words, 10 references, 1 table and/or 1 illustration. An abstract is not required and letters should not be divided into sections. Instructions for references, tables and figures are the same as for full length articles.

    The journal welcomes the opportunity of publishing supplements to regular issues of significant symposia providing the material represents original work not previously published.
    Sponsored symposia should be fully discussed with the Editor prior to agreement to publish.
    Faculty, subject matter and editorial content are all subject to the approval of the editorial office and the journal's integrity and reputation should in no way be compromised.

    1.3 Writing your paper

    The Sage Author Gateway has some general advice and on how to get published, plus links to further resources. Sage Author Services also offers authors a variety of ways to improve and enhance their article including English language editing, plagiarism detection, and video abstract and infographic preparation.

    1.3.1 Make your article discoverable

    When writing up your paper, think about how you can make it discoverable. The title, keywords and abstract are key to ensuring readers find your article through search engines such as Google. For information and guidance on how best to title your article, write your abstract and select your keywords, have a look at this page on the Gateway: How to Help Readers Find Your Article Online.

    Back to top

    2. Editorial policies

    2.1 Peer review policy

    Sage does not permit the use of author-suggested (recommended) reviewers at any stage of the submission process, be that through the web-based submission system or other communication. Reviewers should be experts in their fields and should be able to provide an objective assessment of the manuscript. Our policy is that reviewers should not be assigned to a paper if:

    •  The reviewer is based at the same institution as any of the co-authors

    •  The reviewer is based at the funding body of the paper

    •  The author has recommended the reviewer

    •  The reviewer has provided a personal (e.g. Gmail/Yahoo/Hotmail) email account and an institutional email account cannot be found after performing a basic Google search (name, department and institution). 

    2.2 Authorship

    Papers should only be submitted for consideration once consent is given by all contributing authors. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors.

    The list of authors should include all those who can legitimately claim authorship. This is all those who:

    1. Made a substantial contribution to the concept or design of the work; or acquisition, analysis or interpretation of data,
    2. Drafted the article or revised it critically for important intellectual content,
    3. Approved the version to be published,
    4. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.

    Authors should meet the conditions of all of the points above. When a large, multicentre group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.

    Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on authorship.

    Please note that AI chatbots, for example ChatGPT, should not be listed as authors. For more information see the policy on Use of ChatGPT and generative AI tools.

    2.3 Acknowledgements

    All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.

    2.3.1 Third party submissions

    Where an individual who is not listed as an author submits a manuscript on behalf of the author(s), a statement must be included in the Acknowledgements section of the manuscript and in the accompanying cover letter. The statements must:

    • Disclose this type of editorial assistance – including the individual’s name, company and level of input
    • Identify any entities that paid for this assistance
    • Confirm that the listed authors have authorized the submission of their manuscript via third party and approved any statements or declarations, e.g. conflicting interests, funding, etc.

    Where appropriate, Sage reserves the right to deny consideration to manuscripts submitted by a third party rather than by the authors themselves.

    2.3.2 Writing assistance

    Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance”).

    It is not necessary to disclose use of language polishing services.

    Any acknowledgements should appear first at the end of your article prior to your Declaration of Conflicting Interests (if applicable), any notes and your References.

    2.4 Funding

    Lupus requires all authors to acknowledge their funding in a consistent fashion under a separate heading.  Please visit the Funding Acknowledgements page on the Sage Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. 

    2.5 Declaration of conflicting interests

    It is the policy of Lupus to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles.

    Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your manuscript, after any acknowledgements and prior to the references. If no conflict exists, please state that ‘The Author(s) declare(s) that there is no conflict of interest’. For guidance on conflict of interest statements, please see the ICMJE recommendations here.

    2.6 Research ethics and patient consent

    Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki.

    Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.

    For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.

    Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative.

    Please also refer to the ICMJE Recommendations for the Protection of Research Participants.

    All research involving animals submitted for publication must be approved by an ethics committee with oversight of the facility in which the studies were conducted. The Journal has adopted the ARRIVE guidelines.

    2.7 Clinical trials

    Lupus conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.

    2.8 Reporting guidelines

    The relevant EQUATOR Network reporting guidelines should be followed depending on the type of study. For example, all randomized controlled trials submitted for publication should include a completed CONSORT flow chart as a cited figure and the completed CONSORT checklist should be uploaded with your submission as a supplementary file. Systematic reviews and meta-analyses should include the completed PRISMA flow chart as a cited figure and the completed PRISMA checklist should be uploaded with your submission as a supplementary file. The EQUATOR wizard can help you identify the appropriate guideline.

    Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives.

    2.9 Data

    Sage acknowledges the importance of research data availability as an integral part of the research and verification process for academic journal articles.

    Lupus requests all authors submitting any primary data used in their research articles [alongside their article submissions to be published in the online version of the journal, or provide detailed information in their articles on how the data can be obtained. This information should include links to third-party data repositories or detailed contact information for third-party data sources. Data available only on an author-maintained website will need to be loaded onto either the journal’s platform or a third-party platform to ensure continuing accessibility. Examples of data types include but are not limited to statistical data files, replication code, text files, audio files, images, videos, appendices, and additional charts and graphs necessary to understand the original research. The editor(s) may consider limited embargoes on proprietary data. The editor(s) can also grant exceptions for data that cannot legally or ethically be released. All data submitted should comply with Institutional or Ethical Review Board requirements and applicable government regulations. For further information, please contact the editorial office at 

    Back to top

    3. Publishing Policies

    3.1 Publication ethics

    Sage is committed to upholding the integrity of the academic record. We encourage authors to refer to the Committee on Publication Ethics’ International Standards for Authors and view the Publication Ethics page on the Sage Author Gateway.

    3.1.1 Plagiarism

    Lupus and Sage take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked with duplication-checking software. Where an article, for example, is found to have plagiarised other work or included third-party copyright material without permission or with insufficient acknowledgement, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article; taking up the matter with the head of department or dean of the author's institution and/or relevant academic bodies or societies; or taking appropriate legal action.

    3.1.2 Prior publication

    If material has been previously published it is not generally acceptable for publication in a Sage journal. However, there are certain circumstances where previously published material can be considered for publication. Please refer to the guidance on the Sage Author Gateway or if in doubt, contact the Editor at the address given below.

    3.2 Contributor's publishing agreement

    Before publication, Sage requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement. Sage’s Journal Contributor’s Publishing Agreement is an exclusive licence agreement which means that the author retains copyright in the work but grants Sage the sole and exclusive right and licence to publish for the full legal term of copyright. Exceptions may exist where an assignment of copyright is required or preferred by a proprietor other than Sage. In this case copyright in the work will be assigned from the author to the society. For more information please visit the Sage Author Gateway.

    3.3 Open access and author archiving

    Lupus offers optional open access publishing via the Sage Choice programme and Open Access agreements, where authors can publish open access either discounted or free of charge depending on the agreement with Sage. Find out if your institution is participating by visiting Open Access Agreements at Sage. For more information on Open Access publishing options at Sage please visit Sage Open Access. For information on funding body compliance, and depositing your article in repositories, please visit Sage’s Author Archiving and Re-Use Guidelines and Publishing Policies.

    Back to top

    4. Preparing your manuscript for submission

    Authors are asked to write their manuscripts in English. Spelling and phraseology should conform either to standard UK English or to standard American English and should be consistent throughout the paper.

    The Summary should not exceed 350 words. It should be written in a style that conveys the essential message of the paper in abbreviated form.

    The Introduction should assume that the reader is knowledgeable in the field and should therefore be as brief as possible.

    In the Materials and methods section, methods that have been published in detail elsewhere should not be described in detail. SI units should be used throughout the text.

    Tables and figures should be placed after references and not embedded within the text.

    4.1 Formatting

    The preferred format for your manuscript is Word. The text should be double-spaced throughout and with a minimum of 3cm for left and right hand margins and 5cm at head and foot. Text should be standard 10 or 12 point. LaTeX files are also accepted. Word and (La)Tex templates are available on the Manuscript Submission Guidelines page of our Author Gateway.

    4.2 Artwork, figures and other graphics

    For guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit Sage’s Manuscript Submission Guidelines.  

    Figures supplied in colour will appear in colour online regardless of whether or not these illustrations are reproduced in colour in the printed version. For specifically requested colour reproduction in print, you will receive information regarding the costs from Sage after receipt of your accepted article.

    Each table should be numbered consecutively with an Arabic numeral. Each should have a separate caption or title. Methods not described in the text and abbreviations should be explained at the foot of the table. Footnotes should be designated by superior lower case letters (a, b, c etc). Vertical lines should not be inserted in the table. Tables must be referred to specifically in the text of the paper.

    Lettering should be planned for 50% reduction; text should be readable after reduction. Figures should be referred to as Figure 1, Figure 2 etc. Figures must be referred to specifically in the text of the paper.
    Images should be supplied as bitmap based files (i.e. with .tiff or .jpeg extension) with a resolution of at least 300 dpi (dots per inch). Line art should be supplied as vector-based, separate .eps files (not as .tiff files, and not only inserted in the Word or pdf file), with a resolution of 600 dpi. Images should be clear, in focus, free of pixilation and not too light or dark.

    Colour photographs and Figures - Important information
    Colour photographs and Figures, when accepted, will be published online. In the printed version, they will be in black and white (unless colour prints are paid for). Authors who submit in colour must ensure that their figures are of the highest definition for the black and white version otherwise these may not be accepted. In particular dermatological, immuno-fluorescent and histological figures must be paid for in colour or omitted from the manuscript and replaced in a descriptive format. If, together with your accepted article, you submit usable colour figures, these figures will appear in colour online regardless of whether or not these illustrations are reproduced in colour in the printed version. For specifically requested colour reproduction in print, you will receive information regarding the possible costs from Sage after receipt of your accepted article.

    4.3 Supplementary material

    This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images etc) alongside the full-text of the article. For more information please refer to our guidelines on submitting supplementary files.

    4.4 Reference style

    Lupus adheres to the Sage Vancouver reference style. View the Sage Vancouver guidelines to ensure your manuscript conforms to this reference style.

    If you use EndNote to manage references, you can download the Sage Vancouver EndNote output file.

    It is important that references comply with the style of the journal. Exhaustive lists should be avoided. References should follow the Vancouver format, listed (double-spaced) in numerical order corresponding to the order of citation in the text.

    All authors should be quoted for papers with up to six authors; for papers with more than six authors, the first three only should be quoted followed by et al.

    No issue numbers should be quoted.
    Abbreviations for titles of medical periodicals should conform to those used in the latest editions of Index Medicus and Current Contents. The first and last page numbers for each reference should be provided. Abstracts and letters must be identified as such.

    Papers in press and papers already submitted for publication may be included in the list of references. No citation is required for work that is not yet submitted for publication.

    Personal communications may be allocated a number and included in the list of references in the usual way or simply referred to in the text. Authors must obtain permission from the individual concerned to quote his or her unpublished work.

    Examples of References:
    Journal article:
    1 Derksen RHWM, Bouma BN, Kater L. The association between the Lupus anticoagulant and cerebral infarction in systemic Lupus erythematosus. Scand J Rheumatol 1986; 15: 179-184.
    Journal article, in press:
    2 Mendonca LLF, Khamashta MA, Nelson-Piercy A, Hunt BJ, Hughes GRV. Nonsteroidal anti-inflammatory drugs as a possible cause for reversible infertility. Rheumatology (in press).
    Journal article submitted for publication:
    3 Khamashta MA, Cervera R, Asherson RA. Association of antibodies against phospholipids with heart valve disease in systemic Lupus erythematosus (submitted for publication).
    Complete book:
    4 Wallace DJ, Dubois EL. Dubois' Lupus Erythematosus. Lea & Febiger, 1987, p 51.
    Chapter in book:
    5 Christian CL. Etiologic hypotheses for systemic Lupus erythematosus. In: Lahita RG (ed) Systemic Lupus Erythematosus. Wiley, 1987, 65-79.
    6 Valesini G, Luan FL, Falco M. Clonal analysis of affinity purified anticardiolipin antibodies. Clin Exp Rheumatol 1988; 6: 214 (abstract 102).
    Letter to the Editor:
    7 Sills EM. Systemic Lupus erythematosus in a patient diagnosed as having Shulman disease. Arthritis Rheum 1988; 31: 694 (letter).

    4.5 English language editing services

    Authors seeking assistance with English language editing, translation, or figure and manuscript formatting to fit the journal’s specifications should consider using Sage Language Services. Visit Sage Language Services on our Journal Author Gateway for further information.

    Back to top

    5. Submitting your manuscript

    Lupus is hosted on Sage Track, a web based online submission and peer review system powered by ScholarOne™ Manuscripts. Visit to login and submit your article online.

    If you would like to discuss your paper prior to submission contact the Editor: 
    Prof. Hughes,

    IMPORTANT: Please check whether you already have an account in the system before trying to create a new one. If you have reviewed or authored for the journal in the past year it is likely that you will have had an account created.  For further guidance on submitting your manuscript online please visit ScholarOne Online Help.

    5.1 ORCID

    As part of our commitment to ensuring an ethical, transparent and fair peer review process Sage is a supporting member of ORCID, the Open Researcher and Contributor ID. ORCID provides a unique and persistent digital identifier that distinguishes researchers from every other researcher, even those who share the same name, and, through integration in key research workflows such as manuscript and grant submission, supports automated linkages between researchers and their professional activities, ensuring that their work is recognized. 

    The collection of ORCID iDs from corresponding authors is now part of the submission process of this journal. If you already have an ORCID iD you will be asked to associate that to your submission during the online submission process. We also strongly encourage all co-authors to link their ORCID ID to their accounts in our online peer review platforms. It takes seconds to do: click the link when prompted, sign into your ORCID account and our systems are automatically updated. Your ORCID iD will become part of your accepted publication’s metadata, making your work attributable to you and only you. Your ORCID iD is published with your article so that fellow researchers reading your work can link to your ORCID profile and from there link to your other publications.

    If you do not already have an ORCID iD please follow this link to create one or visit our ORCID homepage to learn more.

    5.2 Information required for completing your submission

    You will be asked to provide contact details and academic affiliations for all co-authors via the submission system and identify who is to be the corresponding author. These details must match what appears on your manuscript. At this stage please ensure you have included all the required statements and declarations and uploaded any additional supplementary files (including reporting guidelines where relevant).

    5.3 Permissions

    Please also ensure that you have obtained any necessary permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please see the Copyright and Permissions page on the Sage Author Gateway.

    Back to top

    6. On acceptance and publication

    6.1 Sage Production

    Your Sage Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will be sent by PDF to the corresponding author and should be returned promptly.  Authors are reminded to check their proofs carefully to confirm that all author information, including names, affiliations, sequence and contact details are correct, and that Funding and Conflict of Interest statements, if any, are accurate.

    6.2 Online First publication

    Online First allows final articles (completed and approved articles awaiting assignment to a future issue) to be published online prior to their inclusion in a journal issue, which significantly reduces the lead time between submission and publication. Visit the Sage Journals help page for more details, including how to cite Online First articles.

    6.3 Access to your published article

    Sage provides authors with online access to their final article.

    6.4 Promoting your article

    Publication is not the end of the process! You can help disseminate your paper and ensure it is as widely read and cited as possible. The Sage Author Gateway has numerous resources to help you promote your work. Visit the Promote Your Article page on the Gateway for tips and advice. 

    Back to top

    7. Further information

    Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to the Lupus editorial office as follows:

    Prof. GRV Hughes 
    Managing Editor: Dr Maria Laura Bertolaccini
    Editorial Assistant: Mrs Den Fletcher

    Individual Subscription, Combined (Print & E-access)

    Institutional Backfile Purchase, E-access (Content through 1998)

    Institutional Subscription, E-access

    Institutional Subscription & Backfile Lease, E-access Plus Backfile (All Online Content)

    Institutional Subscription, Print Only

    Institutional Subscription, Combined (Print & E-access)

    Institutional Subscription & Backfile Lease, Combined Plus Backfile (Current Volume Print & All Online Content)

    Individual, Single Print Issue

    Institutional, Single Print Issue